The researchers analysed the use of antipsychotics and benzodiazepines six months before and six months after persons with Alzheimer’s disease begun using an opioid. These results were then compared to persons with Alzheimer’s disease who did not initiate opioid use. After the initiation of an opioid, the researchers found a downward trend in the prevalence of both antipsychotics and benzodiazepines, with the prevalence of antipsychotics reducing more.
Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.
20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
- Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
- Learn about ITM’s implementation journey and considerations when evaluating the technology
- Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry – Register for FREE
The use of antipsychotics and benzodiazepines is very frequent in persons with Alzheimer’s disease, but it carries a risk for severe adverse effects, and long-term treatment is generally not recommended.
Previous studies have found a decrease in behavioural and psychiatric symptoms of dementia when patients are treated for pain, but this new study now shows, for the first time, a decrease in symptomatic drug use. The study is also the world’s first nationwide study on the subject. The results provide further evidence on the importance of proper diagnosis and treatment of pain among persons with dementia.
The study is part of the MEDALZ cohort, which included 3,327 persons with Alzheimer’s disease diagnosed during 2010-2011. Each person initiating opioid use was matched with a comparison person with Alzheimer’s disease who did not initiate opioid use but was of the same age, gender and region of residence. Data for the study were derived from Finnish nationwide registers.
The results were published in International Psychogeriatrics.
